AR061109A1 - Compuestos y composiciones como inhibidores de la proteasa activadora de canal - Google Patents

Compuestos y composiciones como inhibidores de la proteasa activadora de canal

Info

Publication number
AR061109A1
AR061109A1 ARP070102231A ARP070102231A AR061109A1 AR 061109 A1 AR061109 A1 AR 061109A1 AR P070102231 A ARP070102231 A AR P070102231A AR P070102231 A ARP070102231 A AR P070102231A AR 061109 A1 AR061109 A1 AR 061109A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
ring
alkynyl
alkenyl
Prior art date
Application number
ARP070102231A
Other languages
English (en)
Spanish (es)
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of AR061109A1 publication Critical patent/AR061109A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0821Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
ARP070102231A 2006-05-23 2007-05-23 Compuestos y composiciones como inhibidores de la proteasa activadora de canal AR061109A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80298306P 2006-05-23 2006-05-23
US86060406P 2006-11-22 2006-11-22

Publications (1)

Publication Number Publication Date
AR061109A1 true AR061109A1 (es) 2008-08-06

Family

ID=38565503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102231A AR061109A1 (es) 2006-05-23 2007-05-23 Compuestos y composiciones como inhibidores de la proteasa activadora de canal

Country Status (14)

Country Link
US (2) US7951823B2 (cg-RX-API-DMAC7.html)
EP (1) EP2027143A2 (cg-RX-API-DMAC7.html)
JP (1) JP2009538327A (cg-RX-API-DMAC7.html)
KR (1) KR101069051B1 (cg-RX-API-DMAC7.html)
AR (1) AR061109A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007253819B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0712021A2 (cg-RX-API-DMAC7.html)
CA (1) CA2651762A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007001481A1 (cg-RX-API-DMAC7.html)
MX (1) MX2008014839A (cg-RX-API-DMAC7.html)
PE (1) PE20080708A1 (cg-RX-API-DMAC7.html)
RU (1) RU2419626C2 (cg-RX-API-DMAC7.html)
TW (1) TW200813094A (cg-RX-API-DMAC7.html)
WO (1) WO2007137080A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
KR101069089B1 (ko) * 2006-05-23 2011-09-30 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
MX2008014839A (es) * 2006-05-23 2008-12-05 Irm Llc Compuestos y composiciones en la forma de inhibidores de proteasa de activacion mediante canal.
AU2008214217B2 (en) * 2007-02-09 2011-10-13 Irm Llc Compounds and compositions as channel activating protease inhibitors
EA200901082A1 (ru) * 2007-02-09 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
IE20070935A1 (en) * 2007-12-21 2009-06-24 Trinity College Dublin Guanidine based compounds and their use in the treatment of mental and neurological disorders.
AU2010241084B2 (en) 2009-04-20 2014-10-23 F. Hoffmann-La Roche Ag Proline derivatives as cathepsin inhibitors
MX2012008961A (es) * 2010-02-03 2013-04-29 Meh Associates Inc Fluorometanos multiples sustituidos como isosteros selectivos y bioactivos.
CN103946213A (zh) * 2011-11-25 2014-07-23 霍夫曼-拉罗奇有限公司 作为组织蛋白酶抑制剂的新吡咯烷衍生物
BR112017006920A8 (pt) 2014-10-06 2023-03-07 Quince Therapeutics Inc Inibidores de lisina gingipaína
CN105001131A (zh) * 2015-07-31 2015-10-28 吉尔生化(上海)有限公司 一种医药中间体nα-z-s-苄基-l-半胱氨酸-4-硝基苯酯的合成方法
EP3374352A4 (en) 2015-11-09 2019-10-02 Cortexyme, Inc. GINGIPAINE ARGININE INHIBITORS
MX2019003087A (es) 2016-09-16 2019-08-12 Cortexyme Inc Inhibidores cetónicos de gingipain de lisina.
CN110483437B (zh) * 2018-05-14 2022-12-06 嘉兴维眸生物科技有限公司 一种含五元环的化合物及其制备和应用
JP7672641B2 (ja) 2019-09-17 2025-05-08 メレオ バイオファーマ 4 リミテッド 移植片拒絶反応、閉塞性細気管支炎症候群、及び移植片対宿主病の治療に使用するためのアルベレスタット
WO2021209739A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating respiratory disease mediated by alpha-1 antitrypsin deficiency
CN118265527A (zh) 2021-10-20 2024-06-28 美莱奥生物制药第四有限公司 用于治疗纤维化的中性粒细胞弹性蛋白酶抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809316D0 (en) * 1987-05-11 1988-05-25 Ici America Inc Heterocyclic ketones
US5672582A (en) 1993-04-30 1997-09-30 Merck & Co., Inc. Thrombin inhibitors
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951618B (en) 1994-03-04 1996-08-27 Lilly Co Eli Antithrombotic agents
US5726159A (en) 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
ES2199992T3 (es) 1994-06-02 2004-03-01 Aventis Pharmaceuticals Inc. Nuevos inhibidores de elastasa.
JPH0820597A (ja) 1994-07-07 1996-01-23 Meiji Seika Kaisha Ltd トロンビン阻害作用を有する複素環カルボニル化合物
US5618792A (en) 1994-11-21 1997-04-08 Cortech, Inc. Substituted heterocyclic compounds useful as inhibitors of (serine proteases) human neutrophil elastase
US5914319A (en) 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
CA2176414A1 (en) 1995-05-18 1996-11-19 S. David Kimball Acyl guanidine and amidine prodrugs
US5827866A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6022861A (en) 1995-06-07 2000-02-08 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5827860A (en) 1995-06-07 1998-10-27 Ortho Pharmaceutical Corporation Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6069130A (en) 1995-06-07 2000-05-30 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
US5523308A (en) 1995-06-07 1996-06-04 Costanzo; Michael J. Peptidyl heterocycles useful in the treatment of thrombin related disorders
US6211154B1 (en) 1995-06-07 2001-04-03 Cor Therapeutics, Inc. Ketoheterocyclic inhibitors of factor Xa
IL119466A (en) 1995-11-03 2001-08-26 Akzo Nobel Nv Thrombin inhibitors, their preparation and pharmaceutical compositions containing them
TW523513B (en) 1996-03-01 2003-03-11 Akzo Nobel Nv Serine protease inhibitors
US6291678B1 (en) 1996-06-18 2001-09-18 Warner-Lambert Company Process for the preparation of chiral keto-heterocycles of basic amino acids
IL121474A0 (en) 1996-08-23 1998-02-08 Akzo Nobel Nv Thrombin inhibitors
JP4080541B2 (ja) 1996-10-18 2008-04-23 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子
RU2217436C2 (ru) 1996-12-06 2003-11-27 Кортеч, Инк. Производные оксадиазола, тиадиазола или триазола, являющиеся ингибиторами сериновых протеаз, и содержащие их фармацевтические композиции
US6004933A (en) 1997-04-25 1999-12-21 Cortech Inc. Cysteine protease inhibitors
DE69823178T2 (de) 1997-05-02 2005-06-23 Akzo Nobel N.V. Serine protease inhibitoren
DE69827956T2 (de) 1997-08-11 2005-04-14 Boehringer Ingelheim (Canada) Ltd., Laval Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
EP1114822A3 (en) 1998-06-03 2002-11-13 Cortech Inc. Indoles and tetrahydroisoquinolines containing alpha-keto oxadiazoles as serine protease inhibitors
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6242422B1 (en) 1998-10-22 2001-06-05 Idun Pharmacueticals, Inc. (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
AU3208500A (en) * 1999-01-27 2000-08-18 Ortho-Mcneil Pharmaceutical, Inc. Peptidyl heterocyclic ketones useful as tryptase inhibitors
JP2000256396A (ja) * 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤
GB9929552D0 (en) 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
CA2376965A1 (en) 1999-07-07 2001-01-11 Timothy Patrick Forsyth Peptide boronic acid inhibitors of hepatitis c virus protease
GB9923710D0 (en) 1999-10-08 1999-12-08 Proteus Molecular Design Chemical compounds
JP2003526634A (ja) 1999-12-03 2003-09-09 ブリストル−マイヤーズ スクイブ ファーマ カンパニー C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CN102372764A (zh) 2000-07-21 2012-03-14 先灵公司 用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CA2438272A1 (en) 2001-03-02 2002-10-10 John Macor Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
ATE349463T1 (de) 2001-07-11 2007-01-15 Vertex Pharma Verbrückte bizyklische serinproteaseinhibitoren
AU2002331064B2 (en) 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
WO2003072528A2 (en) 2002-02-08 2003-09-04 Idun Pharmaceuticals, Inc. (substituted)acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
US7205384B2 (en) 2003-08-05 2007-04-17 Ortho-Mcneil Pharmaceutical Inc. Process for preparing peptidyl heterocyclic ketone derivatives
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
KR20060130027A (ko) 2003-10-10 2006-12-18 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 hcv ns3-ns4a 프로테아제의억제제
JP2007513971A (ja) 2003-12-11 2007-05-31 シェーリング コーポレイション C型肝炎ウイルスns3/ns4aプロテアーゼの阻害剤
WO2005076886A2 (en) 2004-02-05 2005-08-25 Irm Llc Prostasin substrates and inhibitors
US7192957B2 (en) 2004-02-27 2007-03-20 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
US8501787B2 (en) 2004-03-24 2013-08-06 Shire Orphan Therapies Gmbh Compounds for the inhibition of angiogenesis and use thereof
JP2008502718A (ja) 2004-05-20 2008-01-31 シェーリング コーポレイション C型肝炎ウイルスns3セリンプロテアーゼのインヒビターとしての置換型プロリン
WO2006006644A1 (ja) 2004-07-14 2006-01-19 Kyowa Hakko Kogyo Co., Ltd. 複素環式化合物
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20060275366A1 (en) 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
KR101069089B1 (ko) 2006-05-23 2011-09-30 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
MX2008014839A (es) * 2006-05-23 2008-12-05 Irm Llc Compuestos y composiciones en la forma de inhibidores de proteasa de activacion mediante canal.
CA2673803A1 (en) 2007-01-10 2008-07-17 Irm Llc Compounds and compositions as channel activating protease inhibitors
AU2008214217B2 (en) 2007-02-09 2011-10-13 Irm Llc Compounds and compositions as channel activating protease inhibitors
EA200901082A1 (ru) 2007-02-09 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы

Also Published As

Publication number Publication date
RU2008150615A (ru) 2010-06-27
US8338469B2 (en) 2012-12-25
WO2007137080A3 (en) 2008-01-24
CA2651762A1 (en) 2007-11-29
US20070275906A1 (en) 2007-11-29
MX2008014839A (es) 2008-12-05
CL2007001481A1 (es) 2008-05-09
JP2009538327A (ja) 2009-11-05
AU2007253819B2 (en) 2011-02-17
KR20090014217A (ko) 2009-02-06
US7951823B2 (en) 2011-05-31
US20110257077A1 (en) 2011-10-20
EP2027143A2 (en) 2009-02-25
RU2419626C2 (ru) 2011-05-27
AU2007253819A1 (en) 2007-11-29
PE20080708A1 (es) 2008-07-30
TW200813094A (en) 2008-03-16
KR101069051B1 (ko) 2011-09-29
BRPI0712021A2 (pt) 2012-01-03
WO2007137080A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
AR061109A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
AR061110A1 (es) Derivados de pirrolidin-2-carboxamida con accion inhibitoria de cap, composiciones farmaceuticas que los comprenden y su utilizacion en el tratamiento de afecciones respiratorias.
AR064841A1 (es) Compuestos y composiciones como como inhibidores de proteasa activadora de canal
ATE387199T1 (de) Neue substanzen und verbindungen als protease- inhibitoren
HRP20040280A2 (hr) SPOJEVI KOJI SADRŽE LAKTAM I NJIHOVI DERIVATI KAOINHIBITORI FAKTORA Xa
ATE466856T1 (de) Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
NO20082629L (no) Macrocyklisk factor VIIa-inhibitorer anvendbare som antikoagulanter
BRPI0410456A (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
PE20091237A1 (es) Derivados de pirrolidina como moduladores de serina proteasas
PE20050940A1 (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
ATE445400T1 (de) Hydantion-derivate als hemmer von matrix- metalloproteinasen
ATE506354T1 (de) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
PE20070839A1 (es) Derivados de indolobenzazepina como inhibidores de ns5b de vhc
PE20121526A1 (es) Compuestos policiclicos heterociclicos como inhibidores del virus de la hepatitis c
DE69902754D1 (de) Heteroaryl-amidinen,-methylamidinen und -guanidinen als protease inhibitoren, insbesondere als urokinase inhibitoren
EA200401436A1 (ru) Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
DE502004009481D1 (de) N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1-piperidincarboxamid-derivate und verwandte verbindungen als cgrp-antagonisten zur behandlung von kopfschmerzen
ATE374773T1 (de) Polycyclische verbindungen als potenten alpha2- adrenoceptor antagonisten
AR054482A1 (es) Derivados de azetidinona para el tratamiento de hiperlipidemias
ECSP066947A (es) Combinaciones farmacológicas que contienen benzoxazina para el tratamiento de enfermedades de las vías respiratorias
SA523441175B1 (ar) N-(2-(4- سيانو ثيازوليدين -3- يل)-2- أوكسو إيثيل)- كينولين -4- كربوكساميدات
UY26847A1 (es) Derivados de la pirrolidina
MXPA01008084A (es) Heteroarilamidinas, metilamidinas y guanidinas como inhibidores de proteasa.
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel

Legal Events

Date Code Title Description
FA Abandonment or withdrawal